DEERFIELD BEACH, Fla., March 5, 2018 (SEND2PRESS NEWSWIRE) — The Pap Corps, Champions for Cancer Research is proud to announce that acclaimed movement artist/choreographer Jon Boogz and The Aqualillies will be headlining their “Inaugural Yacht Hop & Waterside Soiree.” The mega night of mega yachts will take place on Saturday, April 7, 2018 at the famed Turnberry Marina and Turnberry Isle Condominium. This nautical night will support The Pap Corps in their mission to raise research funds for all types of cancer at Sylvester Comprehensive Cancer Center at the University of Miami.
Cancer Research News
News items related to Cancer Research as issued by the Send2Press Newswire service on behalf of the noted news source.
Nationally Renowned Research Doctor Will Discuss His New Hopes, Methods, and Successes with Treating Rare Children’s Cancers on Nov. 5, 2017
| From: Jareds Juggernaut Inc.
LAKE FOREST, Calif., July 15, 2017 (SEND2PRESS NEWSWIRE) — Jareds Juggernaut To Cure Sarcoma, a non-profit which funds researchers of body sparing cancer treatments targeted for rare children’s cancers, today announced an event which features Dr. Charles Keller as the keynote speaker, which will take place on November 5, 2017 in the Sun and Sail Club in Lake Forest, Calif.
Weitz and Luxenberg, P.C. Sees Cancer Research Month As Ideal Time to Provide Free Access to Cancer Study Data
| From: Weitz and Luxenberg P.C.
NEW YORK, N.Y., May 15, 2016 (SEND2PRESS NEWSWIRE) — Weitz & Luxenberg, P.C. today said it agrees with Vice President Joe Biden that the lives of more cancer victims could be saved if cancer researchers were able to more freely access published studies and, most importantly, their underlying data.
California Biotechnology Company Takes Aim at Pancreatic Cancer With an Advanced Phase I/II Clinical Trial Using Rexin-G(TM), a Targeted Injectable Gene Delivery System
| From: Epeius Biotechnologies Corporation
SAN MARINO, Calif. – July 10 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation announced today that an advanced Phase I/II clinical trial using intravenous Rexin-G(TM) for pancreatic cancer that is refractory to standard chemotherapy will open in the summer of 2007 in Los Angeles, California. Rexin-G is the world’s first tumor-targeted injectable gene delivery system that is designed to seek out and destroy both primary tumors and metastatic cancers.